JP2022512373A5 - - Google Patents

Info

Publication number
JP2022512373A5
JP2022512373A5 JP2021533340A JP2021533340A JP2022512373A5 JP 2022512373 A5 JP2022512373 A5 JP 2022512373A5 JP 2021533340 A JP2021533340 A JP 2021533340A JP 2021533340 A JP2021533340 A JP 2021533340A JP 2022512373 A5 JP2022512373 A5 JP 2022512373A5
Authority
JP
Japan
Prior art keywords
disorder
disorders
disease
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533340A
Other languages
English (en)
Japanese (ja)
Other versions
JP7502299B2 (ja
JP2022512373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/084375 external-priority patent/WO2020120450A1/en
Publication of JP2022512373A publication Critical patent/JP2022512373A/ja
Publication of JP2022512373A5 publication Critical patent/JP2022512373A5/ja
Application granted granted Critical
Publication of JP7502299B2 publication Critical patent/JP7502299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533340A 2018-12-12 2019-12-10 置換キサンチン誘導体 Active JP7502299B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18212060.0 2018-12-12
EP18212060 2018-12-12
PCT/EP2019/084375 WO2020120450A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (3)

Publication Number Publication Date
JP2022512373A JP2022512373A (ja) 2022-02-03
JP2022512373A5 true JP2022512373A5 (cg-RX-API-DMAC7.html) 2022-12-16
JP7502299B2 JP7502299B2 (ja) 2024-06-18

Family

ID=64665184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533340A Active JP7502299B2 (ja) 2018-12-12 2019-12-10 置換キサンチン誘導体

Country Status (18)

Country Link
US (2) US11198696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3894410B1 (cg-RX-API-DMAC7.html)
JP (1) JP7502299B2 (cg-RX-API-DMAC7.html)
KR (1) KR102877857B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166151B (cg-RX-API-DMAC7.html)
AU (1) AU2019396499B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008316A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001509A1 (cg-RX-API-DMAC7.html)
DK (1) DK3894410T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2964630T3 (cg-RX-API-DMAC7.html)
HU (1) HUE064908T2 (cg-RX-API-DMAC7.html)
IL (1) IL283768B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007019A (cg-RX-API-DMAC7.html)
PH (1) PH12021551345A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894410T3 (cg-RX-API-DMAC7.html)
TW (1) TWI825243B (cg-RX-API-DMAC7.html)
WO (1) WO2020120450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
KR20250141831A (ko) * 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370372B (es) 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
EP3180340B1 (en) 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
JP7114702B2 (ja) * 2017-07-11 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規置換キサンチン誘導体
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted

Similar Documents

Publication Publication Date Title
RU2015143466A (ru) Нейроактивные стероиды и способы их применения
JP2015512951A5 (cg-RX-API-DMAC7.html)
HRP20220029T1 (hr) Supstituirani derivati ksantina
JP2010520265A5 (cg-RX-API-DMAC7.html)
JP2016513663A5 (cg-RX-API-DMAC7.html)
EA201692558A1 (ru) Производные индолин-2-она или пирролопиридин-2-она
JP2007508358A5 (cg-RX-API-DMAC7.html)
JP2022512374A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
JP2019525939A5 (cg-RX-API-DMAC7.html)
JP2018508592A5 (cg-RX-API-DMAC7.html)
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
BRPI0410378A (pt) tratamento de distúrbios psicóticos e depressivos
JP2015508092A5 (cg-RX-API-DMAC7.html)
JP2020526591A5 (cg-RX-API-DMAC7.html)
JP2020504156A5 (cg-RX-API-DMAC7.html)
RU2017112989A (ru) Соединения и способы
JP2024543135A5 (cg-RX-API-DMAC7.html)
JP2022511730A5 (cg-RX-API-DMAC7.html)
JP2025527291A5 (cg-RX-API-DMAC7.html)
JP2007501270A5 (cg-RX-API-DMAC7.html)
JP2014518552A5 (cg-RX-API-DMAC7.html)
CA3032141A1 (en) Compounds and compositions and uses thereof
JP2011529477A5 (cg-RX-API-DMAC7.html)
JP2013535418A (ja) フェニルカルバメート化合物およびこれを含む筋肉弛緩剤